Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a clinical trial of AT-1501 for the prevention of islet cell rejection in the U.S

Next Previous
Search
Trial Profile

A Phase 2a clinical trial of AT-1501 for the prevention of islet cell rejection in the U.S

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegoprubart (Primary)
  • Indications Islet cell transplant rejection
  • Focus Therapeutic Use

Most Recent Events

  • 24 Mar 2022 According to an Eledon Pharmaceuticals media release, initial open label data from the study is expected in 4Q2022.
  • 14 Feb 2022 According to an Eledon Pharmaceuticals media release, initial data from the study is expected in 2H 2022.
  • 24 Nov 2021 According to an Eledon Pharmaceuticals media release, received IND clearance for AT-1501 to initiate a clinical trial for the prevention of islet cell rejection in the U.S.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top